Kadcyla on course for European approval following CHMP opinion
This article was originally published in Scrip
Executive Summary
Roche has secured a positive opinion from the EU's Committee for Medicinal Products for Human Use ( CHMP) for its oncology candidate Kadcyla, an antibody-drug conjugate which is a follow-up to the breast cancer blockbuster Herceptin.